FLT3 Mutations Confer Enhanced Proliferation and Survival Properties to Multipotent Progenitors in a Murine Model of Chronic Myelomonocytic Leukemia
Open Access
- 1 October 2007
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 12 (4), 367-380
- https://doi.org/10.1016/j.ccr.2007.08.031
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative diseaseLeukemia, 2007
- Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring SystemLeukemia & Lymphoma, 2007
- Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITDBlood, 2006
- Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Blood, 2005
- Activating FLT3 mutations in CD117/KIT+ T-cell acute lymphoblastic leukemiasBlood, 2004
- Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemiaBlood, 2004
- The role of FLT3 in haematopoietic malignanciesNature Reviews Cancer, 2003
- MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemiaNature Genetics, 2001
- HIGH EXPRESSION BUT NO INTERNAL TANDEM DUPLICATION OF FLT3 IN NORMAL HEMATOPOIETIC CELLSPediatric Hematology and Oncology, 1999
- The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotypeImmunity, 1994